Boston University
Diagnostic and therapeutic approaches to hematopoietic stem cell transplant-associated acute kidney injury
Abstract
dc:description.abstractIntroduction. Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication of allogeneic hematopoietic stem cell transplantation (HSCT) characterized by endothelial injury, microangiopathic hemolytic anemia, thrombocytopenia, and end-organ dysfunction. Renal involvement is common, and acute kidney injury is a major contributor to morbidity and mortality in affected patients. However, serum creatinine may underestimate early kidney dysfunction, and the clinical impact of early terminal complement inhibition in adult HSCT-TMA patients remains incompletely defined. Objectives. To evaluate kidney function in patients undergoing allogeneic HSCT and assess the impact of early terminal complement inhibition on renal and survival outcomes in patients with HSCT-TMA. Methods. Two multicenter cohort studies were conducted. Cohort A examined discordance between creatinine- and cystatin C-based estimated glomerular filtration rate (eGFR) and its association with acute kidney injury (AKI) in adults undergoing allogeneic HSCT. The primary outcome was a composite of AKI or death within 90 days post-transplant. Inverse probability weighting and multivariable regression models were used to estimate associations. Cohort B evaluated the effect of early complement C5 inhibitor (C5i) therapy in adults with HSCT-TMA across 12 U.S. transplant centers using a target trial emulation (TTE) framework. Outcomes were compared between patients initiating eculizumab or ravulizumab within 14 days of HSCT-TMA onset and those who did not receive C5 inhibition. Results. Among 274 HSCT recipients in Cohort A, 31% demonstrated discordance between creatinine- and cystatin C-based eGFR estimates. The composite outcome of AKI or death occurred in 51% of patients. After adjustment, eGFR discordance was associated with higher odds of AKI or death (adjusted OR 1.75; 95% CI, 1.03-3.02) and faster time to AKI (HR 1.46; 95% CI, 1.01-2.13). In Cohort B, 238 adults with HSCT- TMA were included, of whom 28.2% received early C5 inhibition. Patients receiving C5 inhibitors demonstrated greater illness severity at HSCT-TMA onset. After IPTW adjustment, early C5 inhibition was associated with a directionally favorable reduction in 90-day mortality (HR 0.63; 95% CI, 0.27-1.48). Discussion. Creatinine-cystatin C eGFR discordance may identify HSCT recipients at increased risk for early kidney injury. Additionally, this multicenter analysis provides one of the largest evaluations of early C5 inhibition in adult HSCT-TMA using a TTE framework, highlighting the need for improved renal risk stratification and rigorous evaluation of complement-directed therapies in this population.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Zargari, Kiana Melody
- Advisors dc:contributor.advisor
-
- Trinkaus-Randall, Vickery
- Gupta, Shruti
- ORCID dc:identifier.orcid
Subjects
dc:subject × 7Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53792